Fortrea Holdings Inc Dossier - Source-backed chat

Fortrea Holdings Inc

FTRENASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.64

Intrinsic Value $18.47median of 3 methodsbased on filings through 30 Jun 2026

Market Price $19.40Price as of 1 Oct 2026

Near fair valueIntrinsic value is 5% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1.8B

Enterprise Value $2.7B

Shares Outstanding 95.1M diluted

Moat Rating None

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Fortrea Holdings Inc. represents a compelling turnaround opportunity in the global contract research organization (CRO) sector. Following its spin-off from Labcorp, the company initially faced operational headwinds, high leverage, and margin compression. However, recent financial results demonstrate a strong commercial recovery, highlighted by three consecutive quarters of book-to-bill ratios above 1.1x (reaching 1.15x in Q1 2026) and robust backlog expansion to $7.85 billion. Driven by disciplined cost management, the exit of legacy Transition Service Agreements (TSAs), and the launch of the AI-enabled Fortrea Intelligent Technology (FIT) suite, Fortrea is well-positioned to expand its margins toward the mid-teens over the next 3 to 5 years. Trading at a significant discount to its larger peers on a price-to-sales basis, the stock offers substantial valuation re-rating potential as profitability normalizes.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$13.00

Mean target$20.55

High · most bullish analyst$26.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$13.00

Macroeconomic headwinds and persistent client budget constraints elongate sales cycles, causing backlog conversion to stall and book-to-bill to fall below 1.0x. Operational inefficiencies or delayed cost-saving realizations limit margin expansion, while the company's high debt burden restricts strategic flexibility and weighs on equity valuation.

Base CaseCentral scenario

$20.55

Matches the consensus mean

Fortrea delivers on its reiterated FY 2026 guidance, with revenues stabilizing between $2.55 billion and $2.65 billion and adjusted EBITDA reaching $190 million to $220 million. Book-to-bill remains healthy at or above 1.05x, supported by steady demand from biotech and large pharma. Margins expand gradually as cost-saving initiatives deliver planned efficiencies, leading to a steady recovery in profitability.

Bull CaseUpside scenario

$26.00

Biotech funding rebounds sharply, driving accelerated backlog conversion and double-digit revenue growth. Fortrea successfully achieves its multi-year margin expansion targets ahead of schedule, reaching mid-teens adjusted EBITDA margins by leveraging its FIT platform and fully optimizing its global workforce. Rapid deleveraging from strong free cash flow conversion drives a multiple re-rating toward the industry average.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum with a Q1 2026 book-to-bill ratio of 1.15x, marking the third consecutive quarter above 1.1x.
Substantial revenue visibility supported by a robust backlog of $7.85 billion as of March 31, 2026.
Significant margin expansion potential driven by the exit of legacy Labcorp TSAs and ongoing cost-optimization initiatives.
Innovation leadership through the launch of the AI-powered Fortrea Intelligent Technology (FIT) suite to modernize clinical trial operations.

Key Investment Risks

High leverage profile with gross debt of over $1.06 billion, which could limit financial flexibility if cash generation underperforms.
Sensitivity to broader biopharma R&D spending and biotech funding cycles.
Intense competition from larger, highly integrated global CROs such as IQVIA and ICON plc.
Execution risks associated with completing the operational transition to a fully standalone company.

Thesis Invalidation Triggers

Trailing twelve-month book-to-bill ratio falling below 1.0x for consecutive quarters.
Significant downward revision of FY 2026 revenue or adjusted EBITDA guidance.
Failure to achieve positive operating cash flow for the full year 2026.
Unexpected operational disruptions or client losses during the transition away from legacy systems.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.